SCHEMBL875217

SCHEMBL875217

[NH]C(=O)c1ccccc1O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.65
HPGD P15428 7/20 0.65
ALDH1A1 P00352 4/20 0.65
HSD17B10 Q99714 4/20 0.65
MAPT P10636 4/20 0.65
TSHR P16473 2/20 0.65
SMN1; SMN2 Q16637 4/20 0.61
CA1 P00915 2/20 0.61
CA9 Q16790 2/20 0.61
CA12 O43570 2/20 0.61
CA2 P00918 2/20 0.61
CA4 P22748 2/20 0.61
CA14 Q9ULX7 2/20 0.61
HMGB1 P09429 1/20 0.61
CA6 P23280 1/20 0.61
CA7 P43166 1/20 0.61
NAPRT Q6XQN6 1/20 0.61
GAA P10253 2/20 0.54
HIF1A Q16665 2/20 0.54
MPO P05164 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9545865 0.83 ALDH1A1 (0.53) KDM4EHPGDALDH1A1HSD17B10MAPT
SCHEMBL3743759 0.80 ALDH1A1 (0.50) KDM4EHPGDALDH1A1HSD17B10MAPT
Salicylamide SCHEMBL21646 0.79 KDM4E (1.00) KDM4EHPGDALDH1A1HSD17B10MAPT
Salicylamide SCHEMBL27497234 0.79 KDM4E (1.00) KDM4EHPGDALDH1A1HSD17B10MAPT
Salicylamide SCHEMBL29384763 0.79 KDM4E (1.00) KDM4EHPGDALDH1A1HSD17B10MAPT
2,2'-Dihydroxybenzphenone SCHEMBL29572496 0.78 HPGD (0.67) KDM4EHPGDALDH1A1HSD17B10MAPT
2,2'-Dihydroxybenzphenone SCHEMBL18422 0.78 HPGD (0.67) KDM4EHPGDALDH1A1HSD17B10MAPT
SCHEMBL29861559 0.78 KDM4E (0.67) KDM4EHPGDALDH1A1HSD17B10MAPT
SCHEMBL9797513 0.78 KDM4E (0.67) KDM4EHPGDALDH1A1HSD17B10MAPT
Salicylamide SCHEMBL18729462 0.77 KDM4E (0.95) KDM4EHPGDALDH1A1HSD17B10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9198426-B2 Use of 5 pyridin-4-yl-1,3-thiazoles for controlling phytopathogenic fungi BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-12-01 US claimed
EP-2658538-A2 PREPARATIONS FOR TOPICAL PREVENTION AND/OR TREATMENT OF ORAL ALLERGIC SYMPTOMS DUE TO ORAL CONTACT WITH FRUITS AND/OR VEGETABLES Harish, M.D. Ziv (US) 2013-11-06 EP claimed
EP-2643000-A2 THERAPEUTIC PIPERAZINES Dart Neuroscience (Cayman) Ltd (KY) 2013-10-02 EP claimed
WO-2012092594-A2 PREPARATIONS FOR TOPICAL PREVENTION AND/OR TREATMENT OF ORAL ALLERGIC SYMPTOMS DUE TO ORAL CONTACT WITH FRUITS AND/OR VEGETABLES HARISH ZIV M D (US) 2012-07-05 WO claimed
WO-2012040258-A2 THERAPEUTIC PIPERAZINES HELICON THERAPEUTICS, INC. (US) 2012-03-29 WO claimed
US-20110065691-A1 THERAPEUTIC PIPERAZINES DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2011-03-17 US claimed
US-20100168185-A1 Use of 5-pyridin-4-yl-1,3-thiazoles for controlling phytopathogenic fungi BAYER CORPSCIENCE AG (DE) 2010-07-01 US claimed
EP-2198710-A1 Use of 5-pyridin-4yl-(1,3) thiazoles for combating phytopathogenic fungi Bayer CropScience AG (DE) 2010-06-23 EP claimed
US-20040142981-A1 Antibacterial benzoic acid derivatives PHARMACIA & UPJOHN COMPANY 2004-07-22 US claimed
US-20040110802-A1 Antibacterial benzoic acid derivatives PHARMACIA & UPJOHN COMPANY 2004-06-10 US claimed
WO-2004018461-A2 ANTIBACTERIAL BENZOIC ACID DERIVATIVES PHARMACIA & UPJOHN COMPANY LLC (US) 2004-03-04 WO claimed
JP-63161052-A None JP disclosed
US-11801252-B2 Pharmaceutical composition JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) 2023-10-31 US disclosed
WO-2023161939-A1 FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF GLUCAGON-LIKE PEPTIDE-1 AND ANALOGS THEREOF ENTERA BIO LTD. (IL) 2023-08-31 WO disclosed
WO-2023161935-A1 FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF GROWTH HORMONE ENTERA BIO LTD. (IL) 2023-08-31 WO disclosed
EP-0037563-A1 Sulfur dyes of the carbazole series, their preparation and application, as well as intermediate compounds CASSELLA Aktiengesellschaft (DE) 1981-10-14 EP disclosed
US-4077948-A N-SALICYLIDENE-N*-SALICYLHYDRAZIDES CIBA-GEIGY CORPORATION (US) 1978-03-07 US disclosed
US-3996282-A Water-soluble quaternary ammonium dyestuffs STERLING DRUG INC. (US) 1976-12-07 US disclosed
US-3994987-A Metal deactivators as adhesion promotors for vulcanizable elastomers to metals CIBA-GEIGY CORPORATION (US) 1976-11-30 US disclosed
US-3935182-A Water-soluble quaternary ammonium heterocyclic azo dyestuffs STERLING DRUG INC. (US) 1976-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168185-A1 Use of 5-pyridin-4-yl-1,3-thiazoles for controlling phytopathogenic fungi PIR, PNPO, PDXK KDM4E 941/4885HPGD 2948/4885ALDH1A1 2137/4885
US-20040142981-A1 Antibacterial benzoic acid derivatives GABRD, PHB1, GABBR1 KDM4E 1582/4885HPGD 1253/4885ALDH1A1 123/4885
US-20110065691-A1 THERAPEUTIC PIPERAZINES PDE4A, PDE4B, PDE4D KDM4E 1159/4885HPGD 1811/4885ALDH1A1 1228/4885
US-20040110802-A1 Antibacterial benzoic acid derivatives GABRD, GABBR1, GABRA1 KDM4E 1240/4885HPGD 1657/4885ALDH1A1 170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.